Obsessive-compulsive disorder (OCD) is a chronic and debilitating illness affecting up to 2-3% of the population. The only medications proven effective for OCD are serotonin reuptake inhibitors (SRIs), but even with SRI treatment, most patients continue to experience significant OCD symptoms, impaired functioning, and diminished quality of life. With the goal of maximizing treatment outcome, the primary aim of this competing continuation/collaborative R01 application is to compare the two SRI augmentation strategies in OCD proven effective in randomized controlled trials: the addition of the antipsychotic medication risperidone (RIS) and the addition of cognitive-behavioral therapy consisting of exposure and ritual prevention (EX/RP). Because prior studies found that even with 6-8 weeks of antipsychotic or EX/RP augmentation, most patients have significant residual OCD symptoms, the second aim is to examine whether patients who benefit from 8 weeks of augmentation will maintain their gains or improve further with continued treatment. Accordingly, during the Acute Augmentation Phase, 100 patients with OCD (50 per site) who have received an adequate SRI trial but still experience clinically significant symptoms will remain on their SRI and be randomized to 8 weeks of one of three adjunctive treatments: 1) twice-weekly EX/RP;2) RIS;or 3) pill placebo. Patients who benefit from the Acute Augmentation Phase will enter the Continuation Phase, and receive the same adjunctive treatment for an additional 24 weeks. This study will be the first to compare the only SRI augmentation strategies for OCD with strong empirical support and to determine whether OCD patients can achieve and maintain an excellent treatment outcome if provided up to 32 weeks of adjunctive treatment. Relevance: Given that most patients who take SRIs for OCD continue to experience significant OCD symptoms, determining how best to augment SRI response and help OCD patients achieve an excellent treatment outcome is an important public health challenge. The long-term goal of the proposed study is to provide clinicians with specific guidelines for how to maximize treatment outcome and help people with OCD lead productive and high quality lives.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH045404-18
Application #
7659472
Study Section
Interventions Research Review Committee (ITV)
Program Officer
Rudorfer, Matthew V
Project Start
1990-09-01
Project End
2011-06-30
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
18
Fiscal Year
2009
Total Cost
$437,521
Indirect Cost
Name
University of Pennsylvania
Department
Psychiatry
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Strauss, Asher Y; Huppert, Jonathan D; Simpson, H Blair et al. (2018) What matters more? Common or specific factors in cognitive behavioral therapy for OCD: Therapeutic alliance and expectations as predictors of treatment outcome. Behav Res Ther 105:43-51
Asnaani, Anu; Kaczkurkin, Antonia N; Alpert, Elizabeth et al. (2017) The effect of treatment on quality of life and functioning in OCD. Compr Psychiatry 73:7-14
Su, Yi-Jen; Carpenter, Joseph K; Zandberg, Laurie J et al. (2016) Cognitive Mediation of Symptom Change in Exposure and Response Prevention for Obsessive-Compulsive Disorder. Behav Ther 47:474-86
Wheaton, Michael G; Carpenter, Joseph K; Kalanthroff, Eyal et al. (2016) Augmenting SRIs for Obsessive-Compulsive Disorder: Patient Preference for Risperidone Does Not Limit Effectiveness of Exposure and Ritual Prevention. Psychother Psychosom 85:314-6
Wheaton, Michael G; Galfalvy, Hanga; Steinman, Shari A et al. (2016) Patient adherence and treatment outcome with exposure and response prevention for OCD: Which components of adherence matter and who becomes well? Behav Res Ther 85:6-12
Foa, Edna B; Simpson, Helen Blair; Rosenfield, David et al. (2015) Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and response prevention or risperidone in adults with obsessive-compulsive disorder. J Clin Psychiatry 76:440-6
McLean, Carmen P; Zandberg, Laurie J; Van Meter, Page E et al. (2015) Exposure and response prevention helps adults with obsessive-compulsive disorder who do not respond to pharmacological augmentation strategies. J Clin Psychiatry 76:1653-7
Wheaton, Michael G; Rosenfield, David; Foa, Edna B et al. (2015) Augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: What moderates improvement? J Consult Clin Psychol 83:926-937
Zandberg, Laurie J; Zang, Yinyin; McLean, Carmen P et al. (2015) Change in obsessive-compulsive symptoms mediates subsequent change in depressive symptoms during exposure and response prevention. Behav Res Ther 68:76-81
Williams, Monnica T; Farris, Samantha G; Turkheimer, Eric N et al. (2014) The impact of symptom dimensions on outcome for exposure and ritual prevention therapy in obsessive-compulsive disorder. J Anxiety Disord 28:553-8

Showing the most recent 10 out of 40 publications